Isoprenoids and related pharmacological interventions: potential application in Alzheimer's disease.
about
Protein prenylation and synaptic plasticity: implications for Alzheimer's diseaseInhibiting geranylgeranylation increases neurite branching and differentially activates cofilin in cell bodies and growth conesCross-talk of membrane lipids and Alzheimer-related proteins.Targeting Rho-GTPases in immune cell migration and inflammation.Role of Phosphatidic Acid Phosphatase Domain Containing 2 in Squalestatin 1-Mediated Activation of the Constitutive Androstane Receptor in Primary Cultured Rat HepatocytesStatins, Bcl-2, and apoptosis: cell death or cell protection?Farnesyltransferase haplodeficiency reduces neuropathology and rescues cognitive function in a mouse model of Alzheimer disease.Impaired geranylgeranyltransferase-I regulation reduces membrane-associated Rho protein levels in aged mouse brain.Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis.Mitochondrial dysfunction--a pharmacological target in Alzheimer's disease.Statins and neuroprotection: basic pharmacology needed.The Role of Geranylgeranyltransferase I-Mediated Protein Prenylation in the Brain.Harnessing the trophic and modulatory potential of statins in a dopaminergic cell line.Exploring the biochemistry of the prenylome and its role in disease through proteomics: progress and potential.Aβ inhibits SREBP-2 activation through Akt inhibition.Geranylgeranyl pyrophosphate is crucial for neuronal survival but has no special role in Purkinje cell degeneration in Niemann Pick type C1 disease.Systemic or Forebrain Neuron-Specific Deficiency of Geranylgeranyltransferase-1 Impairs Synaptic Plasticity and Reduces Dendritic Spine Density.Isoprenoids and protein prenylation: implications in the pathogenesis and therapeutic intervention of Alzheimer's disease.RNAseq analysis of hippocampal microglia after kainic acid-induced seizures.
P2860
Q26858942-75CCE45D-E17B-407E-B4CC-172B9B0FB5E9Q28569470-16AA5B3D-50C0-4990-A71F-72874CB7DF43Q33592538-C60A9696-7941-4237-87FD-D768AE030B7DQ34803380-8161453C-FDC0-4F7E-89E9-83FDFC7D182DQ36618661-EFA25096-A024-43CA-9F49-454F84A42893Q37188822-4B03A370-AF80-4545-B69B-ECC73F610E0AQ37388833-087C83AE-9810-4261-BEBB-AFA6D8B8AFAFQ37722638-0A312877-9AA3-408F-B3E9-ADFCD2C6F76BQ37722680-9C081704-1189-42EA-AB47-FCE2128D8C55Q38007107-70399A73-AEA2-4FA1-910C-26625D46DD22Q38182926-F89F8865-A211-48C3-8C7A-1A65A2606943Q38669055-95A684DF-7B62-4691-82E7-37DFFFC0BB07Q38809645-565A9181-75E2-4CDB-904F-E4AB39D81E96Q39316007-D85000FF-2F15-4CCC-85CF-0D8CC59F4D86Q47419246-D6B74078-12A1-45A9-BF04-386140443625Q48484002-FAFBB4ED-070E-40C5-A3C4-28CD07C09524Q50184556-C13F76CF-1148-47BD-8B6A-6E1D3057A12CQ54223105-539559FD-6CA5-4630-A501-D4A2AFC70F91Q55422256-8C8C9E48-9626-4357-B04E-3E1F993878FE
P2860
Isoprenoids and related pharmacological interventions: potential application in Alzheimer's disease.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Isoprenoids and related pharma ...... cation in Alzheimer's disease.
@ast
Isoprenoids and related pharma ...... cation in Alzheimer's disease.
@en
type
label
Isoprenoids and related pharma ...... cation in Alzheimer's disease.
@ast
Isoprenoids and related pharma ...... cation in Alzheimer's disease.
@en
prefLabel
Isoprenoids and related pharma ...... cation in Alzheimer's disease.
@ast
Isoprenoids and related pharma ...... cation in Alzheimer's disease.
@en
P2093
P2860
P1476
Isoprenoids and related pharma ...... cation in Alzheimer's disease.
@en
P2093
Dongfeng Cao
Marc Parent
Shaowu Cheng
P2860
P2888
P356
10.1007/S12035-012-8253-1
P577
2012-03-15T00:00:00Z